Skip to main content
. 2020 Dec 8;117(51):32584–32593. doi: 10.1073/pnas.1922169117

Fig. 2.

Fig. 2.

Globular adiponectin reduces membrane DAG content and nPKC activation in liver and muscle. (A and B) Western blot images for insulin receptor kinase phosphorylation (pY1162) in liver (n = 5–7) and skeletal muscle (n = 5) of control and gAcrp30-treated mice under the hyperinsulinemic-euglycemic clamp condition. Quantification is shown below. (C) IRS-2–associated PI3K activity in liver. (D) IRS-1–associated PI3K activity in muscle (n = 5). (E and F) Western blot images for Akt phosphorylation (pS473) in liver (n = 5–7) and skeletal muscle (n = 5) in the clamp state. Quantification is shown below. (G) Hepatic plasma membrane sn-1,2-DAG content. (H) Hepatic membrane/cytosolic PKCε ratio. Quantification is shown below. (I) Western blot images for insulin receptor kinase phosphorylation (pY1160) in liver (n = 5). Quantification is shown below. (J) Membrane DAG content in skeletal muscle. (K and L) Membrane/cytosolic PKCθ and PKCε ratio in skeletal muscle. PKCθ and PKCε were probed from the same membrane and therefore have the same corresponding loading controls (GAPDH and Na/K-ATPase). Quantification is shown below. (M and N) Total ceramide content in liver (n = 16) and skeletal muscle. Data are shown as mean ± SEM *P < 0.05, **P < 0.01, ***P < 0.001 by unpaired Student’s t test.